Clinical Trial Update: Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating dasatinib plus quercetin for accelerated aging in schizophrenia and treatment-resistant depression; the trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Treatment-resistant Depression

Drugs mentioned

• DASATINIB (Dasatinib)
• Quercetin (quercetin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Schizophrenia, Treatment Resistant Depression | Phase 2 | Status: ACTIVE_NOT_RECRUITING